[A phase II clinical study of cis-diammine glycolato platinum, 254-S, for gastrointestinal cancers. 254-S Gastrointestinal Cancer Study Group].

A phase II clinical study of 254-S, a new anticancer platinum complex for gastrointestinal cancers, was conducted by the 254-S Gastrointestinal Cancer Study Group consisting of 16 institutions. 254-S was administered at 100 mg/m2 by intravenous drip infusion. This administration was repeated at 4-week intervals. The cases in which 254-S could be administered at least two times were regarded as complete cases evaluable for tumor response; of 75 cases registered, 53 were complete cases (29 cases with esophageal cancer, 12 with stomach cancer and 12 with colon cancer). As a result, 15 partial responses (PR) were obtained in the 29 patients with esophageal cancer and 1 PR from the 12 patients with stomach cancer, for a 51.7% and 8.3% response rate, respectively. 5 PR (55.6%) were obtained in 9 esophageal cancer patients with prior chemotherapy, including 2 PR in 4 patients previously treated with cisplatin. Major toxic effects observed were hematotoxicity including thrombocytopenia (59.0%), leukopenia (68.9%) and anemia (57.4%) and gastrointestinal toxicity such as nausea and vomiting (63.9%) and anorexia (41.0%); since grade 3 or 4 thrombocytopenia was observed with an incidence of 27.9%, careful monitoring seems to be required during the treatment with this product. Abnormal parameter changes on renal function included elevations of BUN (18.0%) and serum creatinine (9.8%). Based on these results, it was concluded that 254-S is a useful anticancer agent for the treatment of esophageal cancer.
AuthorsT Taguchi, A Wakui, K Nabeya, M Kurihara, K Isono, T Kakegawa, K Ota
JournalGan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 19 Issue 4 Pg. 483-8 (Apr 1992) ISSN: 0385-0684 [Print] JAPAN
PMID1558398 (Publication Type: Clinical Trial, English Abstract, Journal Article, Multicenter Study)
Chemical References
  • Antineoplastic Agents
  • Organoplatinum Compounds
  • nedaplatin
  • Antineoplastic Agents (adverse effects, therapeutic use)
  • Colonic Neoplasms (drug therapy)
  • Drug Administration Schedule
  • Drug Evaluation
  • Esophageal Neoplasms (drug therapy)
  • Humans
  • Infusions, Intravenous
  • Leukopenia (chemically induced)
  • Middle Aged
  • Nausea (chemically induced)
  • Organoplatinum Compounds (adverse effects, therapeutic use)
  • Stomach Neoplasms (drug therapy)
  • Thrombocytopenia (chemically induced)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: